MMP inhibition and downregulation by bisphosphonates

Annals of the New York Academy of Sciences

Volumn 878, Issue , 1999, Pages 453-465

  Teronen, Olli ^a,b   Heikkilä, Pia ^a   Konttinen, Yrjö T ^a,b   Laitinen, Minna ^d   Salo, Tuula ^c   Hanemaaijer, Roeland ^e   Teronen, Anneli ^a   Maisi, Päivi ^a,b   Sorsa, Timo ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c UNIVERSITY OF OULU   (Finland)

^d UNIVERSITY OF TAMPERE   (Finland)

^e TNO   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CLONDRINATE; COLLAGENASE; COLLAGENASE 3; GELATINASE A; GELATINASE B; MACROPHAGE ELASTASE; MATRIGEL; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MESSENGER RNA; NEDRINATE; NEUTROPHIL COLLAGENASE; PAMIDRONIC ACID; STROMELYSIN; UNCLASSIFIED DRUG; ZOLENDRONATE;

BONE METASTASIS; CANCER CELL CULTURE; CANCER INVASION; CONFERENCE PAPER; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; FIBROSARCOMA; HUMAN; HUMAN CELL; MELANOMA; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PAGET BONE DISEASE;

EID: 0032863323     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1999.tb07702.x     Document Type: Conference Paper

References (53)

1. 1. Gross, J. & C.M. Lapiére. 1962. Collagenolytic activity in amphibian tissue culture assay. Proc. Natl. Acad. Sci. USA 54: 1197-1204.
2. 2. Golub, L.M. et al. 1983. Minocycline reduces gingival collagenolytic activity during diabetes. Preliminary observations and a proposed new mechanism of action. J. Periodont. Res. 18: 516-526.
3. 3. Golub, L.M. et al. 1992. Host modulation with tetracyclines and their chemically modified analogues. Curr. Opin. Dent. 2: 80-90.
4. 4. Golub, L.M. et al. 1997. A matrix metalloproteinase inhibitor reduces bone-type collagen degradation fragments and specific collagenases in gingival crevicular fluid during adult periodontitis. Inflamm. Res. 46: 310-319.
5. 5. Ingman, T. et al. 1993. Tetracycline inhibition and the cellular source of collagenase in gingival crevicular fluid in different periodontal diseases. J. Periodontol. 64: 82-88.
6. 6. Lauhio, A. et al. 1994. Reduction of matrix metalloproteinase 8-neutrophil collagenase levels during long-term doxycycline treatment of reactive arthritis. Antimicrob. Agents Chemother. 38: 400-402.
7. 7. Lauhio, A. et al. 1994. In vivo inhibition of human neutrophil collagenase (MMP-8) activity during long-term combination therapy of doxycycline and NSAID in acute reactive arthritis. Clin. Exp. Immunol. 98: 21-28.
8. 8. Lauhio, A. et al. 1995. Tetracyclines in the treatment of rheumatoid arthritis. Lancet. 340: 645-646.
9. 9. Nordström, D. et al. 1998. Anti-collagenolytic mechanism of action of doxycycline treatment in rheumatoid arthritis. Rheumatol. Int. 5: 175-180.
10. 10. Brown, P.D. & R. Giavazzi. 1995. Matrix metalloproteinase inhibition: a review of anti-tumour activity. Ann. Oncol. 6: 967-974.
11. 11. Delmas, P.D. 1996. Bisphosphonates in the treatment of bone diseases. N. Engl. J. Med. 335: 1836-1837.
12. 12. Hortobagyi, G.N. et al. 1996. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N. Engl. J. Med. 335: 1785-1791.
13. 13. Bankhead, C. 1997. Bisphosphonates spearhead new approach to treating bone metastases. J. Natl. Cancer Inst. 89: 115-116.
14. 14. Diel, I.J. et al. 1998. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N. Engl. J. Med. 339: 357-363.
15. 15. van der Pluijm, G. et al. 1996. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J. Clin. Invest. 98: 698-705.
16. 16. Igarashi, K. et al. 1996. Inhibitory effect of the topical administration of a bisphosphonate (risedronate) on root resorption incident to orthodontic tooth movement in rats. J. Dent. Res. 75: 1644-1649.
17. 17. Sasaki, A. et al. 1995. Bisphosphonate risendronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res. 55: 3551-3557.
18. 18. Yoneda, T. et al. 1997. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J. Clin. Invest. 99: 2509-2517.
19. 19. Jeffcoat, M.K. & M.S. Reddy. 1996. Alveolar bone loss and osteoporosis: Evidence for a common mode of therapy using the bisphosphonate alendronate. In: Biological Mechanisms of Tooth Movement and Craniofacial Adaptation. Z. Davidowitch & L.A. Norton, Eds.: 365-373. Harvard Society for Advancement of Orthodontics, Boston, MA.
20. 20. Reddy, M.S. et al. 1995. Alendronate treatment of naturally occuring periodontitis in beagle dogs. J. Periodontol. 66: 211-217.
21. 21. Weinreb, M. et al. 1994. Histomorphometrical analysis of the effects of the bisphosphonate alendronate on bone loss caused by experimental periodontitis in monkeys. J. Periodont. Res. 29: 35-40.
22. 22. Fleisch, H. et al. 1991. Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone diseases. Drugs. 42: 919-944.
23. 23. Fleisch, H. et al. 1997. Bisphosphonates in bone disease. From laboratory to the patient. The Parthenon Publishing Group. New York.
24. 24. Rodan, G.A. & H.A. Fleisch. 1996. Bisphosphonates: mechanisms of action. J. Clin. Invest. 97: 2692-2696.
25. 25. Felix, R. et al. 1976. The effect of several diphosphonates on acid phosphohydrolases and other lysosomal enzymes. Biochim. Biophys. Acta 429: 429-438.
26. 26. Skorey, K. et al. 1997. How does alendronate inhibit protein-tyrosine phosphatases? J. Biol. Chem. 272: 22472-22480.
27. 27. Smith, A. et al. 1996. Protein-tyrosine phosphatase activity regulates osteoclast formation and function: inhibition by alendronate. Proc. Natl. Acad. Sci. USA 93: 3068-3073.
28. 28. Teronen, O. et al. 1995. Characterization of interstitial collagenases in jaw cyst walls. Eur. J. Oral Sci. 103: 141-147.
29. 29. Teronen, O. et al. 1997. Inhibition of matrix metalloproteinase-1 by dichloromethylene bisphosphonate (clodronate). Calcif. Tissue Int. 61: 59-61.
30. 30. Teronen, O. et al. 1997. Human neutrophil collagenase MMP-8 in peri-implant sulcus fluid and its inhibition by clodronate. J. Dent. Res. 76: 1529-1537.
31. 31. Sorsa, T. et al. 1994. Effects of tetracyclines on neutrophil, gingival, and salivary collagenases. A functional and western-blot assessment with special reference to their cellular sources in periodontal diseases. Ann. N.Y. Acad. Sci. 732: 112-131.
32. 32. Sorsa, T. et al. 1997. Activation of type IV procollagenenase by human tumor-associated trypsin-2. J. Biol. Chem. 272: 21067-21074.
33. 33. Teronen, O. et al. 1995. Identification and characterization of gelatinases/type IV collagenases in jaw cysts. J. Oral Pathol. Med. 24: 78-84.
34. 34. Decarlo, A. 1994. Matrix metalloproteinase activation and induction in keratinocytes by a purified thiol-proteinase from Porphyromonas gingivalis. PhD thesis, University of Alabama at Birmingham, Alabama, USA.
35. 35. Lichte, A. et al. 1996. The recombinant catalytic domain of membrane-type matrix metalloproteinase-1 (MT1-MMP) induces activation of progelatinase A and progelatinase A complexed with TIMP-2. FEBS Lett. 397: 277-282.
36. 36. Verheijen, J.H. et al. 1997. Modified proenzymes as artificial substrates for proteolytic enzymes: colorimetric assay of bacterial collagenase and matrix metalloproteinase activity using modified pro-urokinase. Biochem J. 323: 603-609.
37. 37. Risteli, L. & J. Risteli. 1987. Analysis of extracellular matrix proteins in biological fluids. Meth. Enzymol. 145: 391-411.
38. 38. Mäkelä, M. et al. 1994. Matrix metalloproteinases (MMP-2 and MMP-9) of oral cavity: cellular origin and relationship to periodontal status. J. Dent. Res. 73: 1397-1406.
39. 39. Teronen, O. 1998. Jaw cyst matrix metalloproteinases (MMPs) and inhibition of MMPs by bisphosphonates. PhD thesis, University of Helsinki, Helsinki, Finland.
40. 40. Nakaya, H. et al. 1997. Effects of bisphosphonate on MMP-1 activity and mRNA expression. J. Dent. Res. 76: A2725.
41. 41. Nakaya, H. et al. 1997. Effects of bisphosphonates on MMP-3 activity and mRNA expression [abstract]. Annual meeting of the American Academy of Periodontology.
42. 42. Golub, L.M. et al. 1985. Further evidence that tetracyclines inhibit collagenase activity in human crevicular fluid and from other mammalian sources. J. Periodont. Res. 20: 12-23.
43. 43. Ryan, M.E. et al. 1996. Matrix metalloproteinases and their inhibition in periodontal treatment. Curr. Opin. Periodont. 3: 85-96.
44. 44. Jonat, C. et al. 1996. Transcriptional downregulation of stromelysin by tetracycline. J. Cell. Biochem. 60: 341-347.
45. 45. Suomalainen, K. et al. 1992. Tetracycline inhibition identifies the cellular origin of interstitial collagenases in human periodontal diseases in vivo. Oral Microbiol. Immunol. 7: 121-123.
46. 46. Chambers, A.F. & L.M. Matrisian. 1997. Changing views of the role of matrix metalloproteinases in metastasis. J. Natl. Cancer Inst. 89: 1260-1270.
47. 47. Seftor, R.E. et al. 1998. Chemically modified tetracyclines inhibit human melanoma cell invasion and metastasis. Clin. Exp. Metastasis. 16: 217-225.
48. 48. Sato, M. et al. 1991. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J. Clin. Invest. 88: 2095-2105.
49. 49. Siris, E.S. 1997. Breast cancer and osteolytic metastases: Can bisphosphonates help? Nat. Med. 2: 151-152.
50. 50. Delmas, P.D. 1996. Bisphosphonates in the treatment of bone diseases. N. Engl. J. Med. 335: 1836-1837.
51. 51. Farina, A.R. et al. 1998. Tissue inhibitor of metalloproteinase-2 protection of matrix metalloproteinase-2 from degradation by plasmin is reversed by divalent cation chelator EDTA and the bisphosphonate alendronate. Cancer Res. 58: 2957-2960.
52. 52. Ramamurthy, N.S. et al. 1999. A suboptimal CMT-8 clodronate combination therapy inhibits alveolar bone resorption in LPS induced periodontitis in rats. Ann. N.Y. Acad. Sci. This volume.
53. 53. Hanemaaijer, R. et al. 1997. Matrix metalloproteinase-8 is expressed by rheumatoid synovial fibroblasts and endothelial cells. J. Biol. Chem. 272: 31504-31509.